Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$67.25M, compared with -$49.76M a year earlier.
Context
- Net debt amounted to 13.5% of total assets at the end of Q1 FY2026, down 3.0 pp from a year earlier.
- Net debt grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -35.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (41.16M) USD
- Year-over-year change
- +25.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (41.16M) | +25.6% |
| FY2024 | 2024-12-31 | (55.33M) | +18.7% |
| FY2023 | 2023-12-31 | (68.02M) | -228.2% |
| FY2022 | 2022-12-31 | (20.72M) | — |
Net Debt vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 net debt of -$67.25M is the 4th highest of the 10 companies compared; the peer median is -$146.66M.
- Its year-over-year change of -35.1% is the 5th highest of 10, against a peer median of -92.1%.
- Net debt amounts to 13.5% of total assets for RAPP, versus a peer median of 51.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | -$13.2M | +19.8% | — | 5.1% |
| Mar 2026 | -$30.67M | -94.2% | — | 84.9% | |
| Mar 2026 | -$50.12M | -14.5% | — | 12.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$67.25M | -35.1% | — | 13.5% |
| Jun 2026 | -$100.64M | -17.4% | — | 13.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$146.66M | -16.5% | — | 95.3% |
| Mar 2026 | -$258.07M | -92.1% | — | 93.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | -$317.21M | -2931.4% | — | 80.6% |
| Sep 2026 | -$361.12M | -142.2% | — | 27.5% | |
| Sep 2026 | -$919.12M | -352.4% | — | 51.2% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | -$146.66M | -92.1% | — | 51.2% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.